What procedural mitigation strategies can the FDA consider for fighting future pandemics via the logistics of adequate blood supplies?

Question

description

Here is the research question and the 5 subareas of focus for our research:

What procedural mitigation strategies can the FDA consider for fighting future pandemics via the logistics of adequate blood supplies?

Number 3 is the one im asking for assistance on.

1.     What is the foundation of blood supply acquisition in the US? When and why did the federal government and FDA started regulating the acquisition of blood products?

2.     What is the history of and current FDA standards for blood acquisition?

3.     What is the history of the process for temporary and permanent changes in FDA policies involving blood acquisition?

4.     What procedural modifications were effective for past pandemic-type events that impacted blood supplies?

5.     What, if any, COVID-19 mitigations have been applied successfully and unsuccessfully?

 5